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Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling multisystem
chronic disease. The etiology and pathogenesis of ME/CFS are unknown. Infections of
cytomegalovirus (CMV), Epstein‐Barr virus (EBV), and human herpesvirus‐6 (HHV‐6) are
suspected as etiological agents for ME/CFS. This study aims to estimate prevalence and
type (active/latent) of EBV, CMV, and HHV‐6 infections in Bulgarian ME/CFS patients. In
the study were included 58 patients with ME/CFS and 50 healthy controls. Virus‐specific
antibodies were detected by enzyme‐linked immunosorbent assay and viral genomic
sequences in peripheral blood mononuclear cell (PBMCs) and plasma samples by nested
polymerase chain reaction (PCR). We did not observe any significant differences in virus‐
specific immunoglobulin G and immunoglobulin M positivity rates between patients with
ME/CFS and control group. In ME/CFS plasma samples, EBV DNA was found in 24.1%,
CMV DNA in 3.4%, and HHV‐6 DNA in 1.7% of samples. EBV DNA was detected in 4%,
and CMV and HHV‐6 DNA were not found in plasma samples of controls. The frequency
of viral genome detection in PBMCs of patients and controls was 74% vs 78% for CMV,
81% vs 84% for EBV, and 82.8% vs 82% for HHV‐6. The difference in frequency of EBV
active infection in ME/CFS and control group was statistically significant (P= .0027). No
ME/CFS and control individuals with active CMV and HHV‐6 infection were observed. In
conclusion, this study using both serological and PCR‐based techniques for distinguishing
between active and latent infection showed high rate of active EBV infection among
patients with ME/CFS indicating that at least in a subset of cases, EBV is important factor
for the development of disease.
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1 | INTRODUCTION
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a
disabling multisystem chronic disease. The main clinical sign is de-
bilitating persisting chronic fatigue, not relieved by rest. In addition
to fatigue, patients with ME/CFS also suffer from a variety of other
symptoms including postexertional malaise, cognitive impairment,
musculoskeletal pain, sleep dysfunction, sore throats, lymphade-
nopathy, orthostatic intolerance, and gastrointestinal symptoms.
The disease is poorly understood and no diagnostic biomarkers are
currently available. Therefore, the diagnosis of ME/CFS is difficult
and requires exclusion of other medical conditions. It is based on
several different sets of diagnostic criteria/case definitions, of
which the most widely used are Fukuda case definition, Canadian
consensus criteria, and International Consensus Criteria.1‐3 The
etiology and pathogenesis of ME/CFS are still unknown. Dysregu-
lation of immune system, autonomic nervous system, and metabolic
disturbances are the most popular explanatory models for ME/CFS.4‐8
The hypotheses for etiology include genetic predisposition, immune
dysfunction, infectious agents, metabolic disturbances, brain dys-
function, toxins, stress, trauma, circulatory abnormalities, or a
combination of any of these factors. As in many patients with
ME/CFS, the disease starts suddenly with a “flu‐like’’ illness, it was
suggested that an infectious agent can trigger the syndrome.
Numerous viruses have been associated with the development of
ME/CFS including enteroviruses, herpesviruses, retroviruses, par-
vovirus B19, hepatitis C virus, Ross River virus (RRV).8‐15 It was
shown that the severity of acute Epstein‐Barr virus (EBV) and RRV
infection and the host response may determine the course of
postinfectious fatigue and ME/CFS and was suggested that in-
flammatory cytokines influence the CNS, resulting in neurocogni-
tive disturbances.16,17 In addition, according to Duvignaud et al,18
CFS‐like illness may develop in 26% of patients with chronic fatigue
as a result of postchikungunya chronic disease, induced by
chikungunya virus. However, although the correlation between viral
infections and ME/CFS has been studied for a long time, the role of
viruses in the etiology of ME/CFS is still uncertain.
Herpesviruses have frequently been associated with ME/CFS.
Infections with EBV, human herpesvirus‐6 (HHV‐6), and cytomega-
lovirus (CMV) are considered as triggering factors for ME/CFS.9
After an acute infection, these viruses persist life‐long in various cells
of the body and may reactivate. There are hypotheses that the
reactivation of a latent virus could damage the immune system and
contribute to the morbidity of ME/CFS. Another possibility is that
patients with ME/CFS are susceptible to acute viral infections as
a consequence of immune dysfunction. At the same time, these
viruses are ubiquitous in the general population and, therefore, it is
difficult to prove their causative roles.
Despite multiple studies on the association of EBV, CMV, and
HHV‐6 with ME/CFS, the data are not consistent. This study aims
to estimate the prevalence and type of EBV, CMV, and HHV‐6
infections in Bulgarian patients with ME/CFS using both serological
and polymerase chain reaction (PCR)‐based techniques.
2 | MATERIALS AND METHODS
2.1 | Study participants
A total of 108 subjects were recruited for this study—58 patients
with ME/CFS and 50 healthy persons as a control group. The
patients were diagnosed with ME/CFS according to Fukuda
criteria.1 They were aged between 19 and 60 years (average
39 years) and women were more prevalent (72%) than men (28%).
The control group included 34 females and 16 males with average
age of 42 years.
2.2 | Ethical issues
This study has been approved by the Ethical Committee of the
National Center of Infectious and Parasitic Diseases, Sofia,
Bulgaria. All participants provided informed written consent before
their enrollment.
2.3 | Sample collection and processing
Blood samples were collected in ethylenediaminetetraacetic acid
(for peripheral blood mononuclear cells [PBMCs] and plasma) and
Gel/Clot Activator (for serum) vacutainers. PBMCs were prepared
from whole blood by Histopaque‐1077 (Sigma‐Aldrich) density
gradient separation. Serum samples were used for enzyme‐linked
immunosorbent assay (ELISA) testing. DNA was isolated from PBMCs
and blood plasma samples.
2.4 | Enzyme‐linked immunosorbent assay
ELISA testing was used to detect immunoglobulin G (IgG) and im-
munoglobulin M (IgM) class antibodies specific to CMV, EBV, and
HHV‐6. All serum samples were tested by using commercial ELISA
kits for the following virus‐specific antibodies: CMV IgM and IgG,
EBV capsid antigen (CA) IgM and IgG, (EUROIMMUN, Medizinische
Labordiagnostika AG, Lubeck, Germany); HHV‐6 IgG and IgM
(VIDIA, Vestec, Czech Republic). The EBV‐CA positive samples
were further tested for the presence of EBV nuclear antigen 1
(EBNA‐1) IgG (EUROIMMUN, Medizinische Labordiagnostika AG).
Performance and interpretation of results of all tests were done
according to the manufacturer's instructions. Each ELISA was
run with negative and positive controls, and calibrator (cutoff).
For each measurement of an antibody concentration, a ratio (R)
(EUROIMMUN) and index value (Iv) (VIDIA) were calculated as
follows: sample optical density (OD) value was divided by cutoff
OD value. Serum samples with R ≥ 1.1 (EUROIMMUN) and Iv > 1
(VIDIA) were regarded as positive. Test results with R/Iv > 5.0
were for the purpose of this study considered as highly positive.
Samples with equivocal results were retested.
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2.5 | Nested polymerase chain reaction
DNA was isolated from PBMCs using PureLink Genomic DNA Mini
Kit (Invitrogen) and from cell‐free blood plasma by PureLink Viral
RNA/DNA Mini Kit (Invitrogen) according to the manufacturer's
instructions. The quality of the PBMCs DNA and the absence
of contamination of plasma DNA by cellular DNA were evaluated
by β‐globin gene amplification as previously described.19 Nested
polymerase chain reaction (nPCR) was used to amplify specific
CMV, EBV, and HHV‐6 DNA sequences in PBMCs and cell‐free
blood plasma from patients with ME/CFS and healthy controls.
Detection of CMV, EBV, and HHV‐6 DNA by nPCR was mainly
based on previous studies of Allen et al,20 Cinque et al,21 and
Secchiero et al,22 respectively. The reaction volume of the first
and second PCR was 50 μL and included AmpliTaq Gold 360
Master Mix (Applied Biosystems), 10 pmol of each primer,
nuclease‐free water, and 10 μL of template. The primers used for
amplification of CMV, EBV, and HHV‐6 DNA sequences are
described in Table 1. They targeted conserved regions of virus
genome: glycoprotein H gene of CMV, main capsid protein gene of
HHV‐6, and EBNA‐1 of EBV. Positive and negative controls were
included in each experiment. DNA positive controls for CMV and
EBV were purchased from Genekam Biotechnology AG (Duisburg,
Germany) and for HHV‐6 was a gift from Prof M. Murovska
(Institute of Microbiology and Virology, Riga Stradiņš University,
Latvia). As negative controls DNA from CMV, EBV, and HHV‐6
negative individuals, as well as water controls, were used. The
cycling conditions were as follows: for both cycles of CMV—initial
denaturation at 94°C for 3 minutes, followed by 40 cycles
(94°C/30 seconds, 56°C/30 seconds, and 72°C/45 seconds) and
final extension for 5 minutes at 72°C; for both cycles of
HHV‐6—initial denaturation at 94°C for 3 minutes, followed by
30 cycles (94°C/1 minute, 57°C/1 minute, and 72°C/1 minute)
and terminal extension for 5 minutes at 72°C; first cycle of
EBV—initial denaturation for 3 minutes at 94°C, 40 cycles
(94°C/30 seconds, 55°C/30 seconds, and 72°C/45 seconds),
terminal extension for 5 minutes at 72°C; during the second cycle
of EBV DNA amplification, the annealing temperature was 60°C.
PCR products were analyzed by electrophoresis in 2% agarose
gels, stained with ethidium bromide and observed under UV light. A
result was considered positive when both the sample and positive
control in the second round of PCR presented a band corresponding
to 159‐bp (CMV), 209‐bp (EBV), and 258‐bp (HHV‐6) DNA fragment,
while there was no band in the negative control. All virus‐positive
plasma samples were retested.
2.6 | Quantitative real‐time PCR
The viral load of EBV in plasma samples from ME/CFS patients
with active viral infection was determined using Sacace EBV
Real‐TM Quant Kit, based on EBV LMP‐gene DNA amplification
(Sacace Biotechnologies Srl, Como, Italy) according to the
manufacturer's instructions. The amplifications were carried
out in Exicycler 96 thermocycler from Bioneer (Bioneer Corp,
South Korea).
2.7 | Statistical analysis
Analysis of data was performed with SPSS for Windows v.10.0.
Fisher's exact test was used to test for a statistically significant
difference in the frequency of positivity of virus‐specific markers, as
well of active and latent CMV, EBV, and HHV‐6 infection between
TABLE 1 Primers used in nPCR assaysPrimers Primer sequences (5′‐3′) Amplicon, bp Target region
CMV Glycoprotein H gene
External primers TGGACCTGGCCAAACGAGCCC 205
TGGACGAGGCTGCCCATGAGG
Internal primers TCACCGACATCACCAGCCTCG 159
CTTGGCGCGCGAAGGCTGAAAG
EBV EBNA‐1 gene
External primers AAGGAGGGTGGTTTGGAAAG 297
AGACAATGGACTCCCTTAGC
Internal primers ATCGTGGTCAAGGAGGTTCC 209
ACTCAATGGTGTAAGACGAC
HHV‐6 Main capsid
protein geneExternal primers GCGTTTTCAGTGTGTAGTTCGGCAG 520
TGGCCGCATTCGTACAGATACGGAGG
Internal primers GCTAGAACGTATTTGCTGCAGAACG 258
ATCCGAAACAACTGTCTGACTGGCA
Abbreviations: CMV, cytomegalovirus; EBNA‐1, EBV nuclear antigen 1; EBV, Epstein‐Barr virus;
HHV‐6, herpesvirus‐6; nPCR, nested polymerase chain reaction.
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ME/CFS patient group and control group. P < .05 were considered
statistically significant.
3 | RESULTS
3.1 | CMV, EBV, and HHV‐6 serology
All serum specimens were tested for the presence of serum
antibodies (both IgG and IgM) against CMV, EBV‐CA, and HHV‐6 by
ELISA. The data are presented in Table 2. Specific anti‐CMV IgG
antibodies were detected in 86.2% (50/58) and anti‐CMV IgM in
5.2% (3/58) of ME/CFS serum samples and in 88% (44/50) and 2%
(1/50) of control samples, respectively. Anti‐EBV‐CA IgG antibodies
were found in 96.6% (56/58), anti‐EBV‐CA IgM in 8.6% (5/58) of
serum samples from ME/CFS cases. In the control group, we found
98% (49/50) EBV‐CA IgG positivity, none of the serum samples was
positive for EBV‐CA IgM. In the ME/CFS group, 96.6% (56/58) and
8.6% (5/58) of serum samples were positive for HHV‐6 IgG and IgM,
respectively. In the control group, 98% (49/50) of samples were IgG
positive and 6% (3/50) were IgM positive. All CMV, EBV, and HHV‐6
IgM positive samples were also IgG positive. All EBV‐CA positive
cases were also positive for EBNA‐1 IgG antibodies.
For all three viruses (CMV, EBV, and HHV‐6), we did not observe
any statistically significant differences in IgG and IgM positivity
rates between ME/CFS patients and control group (P = .0601‐1, for
tested serological markers).
3.2 | Detection of viral DNA by nPCR
3.2.1 | CMV, EBV, and HHV‐6 genomic sequences
in plasma samples
Of all 58 tested plasma samples from patients with ME/CFS, CMV
DNA was found in 3.4% (2/58), EBV DNA in 24.1% (14/58), and
HHV‐6 DNA in 1.7% (1/58) of the samples (Table 3). EBV DNA
was detected in 4% (2/50) of control plasma samples. CMV
and HHV‐6 DNAs were not found in healthy individuals. The
difference in EBV DNA detection in plasma samples of ME/CFS
and control groups was statistically significant (P = .0052). There
was no statistically significant difference for CMV (P = .4981) and
HHV‐6 (P = 1.00).
3.2.2 | EBV, CMV, and HHV‐6 DNA in PBMCs
CMV DNA was found in 74.1% (43/58), EBV DNA in 81% (47/58),
and HHV‐6 DNA in 82.8% (48/58) of the PBMCs samples from
patients with ME/CFS. In PBMC DNA samples of the control
group, CMV, EBV, and HHV‐6 DNA were detected in 78%
(39/50), 84% (42/50), and 82% (41/50), respectively (Table 3).
There was no statistically significant difference between ME/CFS
patients and the control group concerning CMV (P = .6597),
EBV (P = .8018), and HHV‐6 (P = 1.00) DNA detection in
PBMCs samples.
TABLE 2 CMV, EBV, and HHV‐6














n (%) n (%) n (%) n (%) n (%) n (%)
Patients with ME/
CFS n = 58
50 (86.2%) 3 (5.2%) 56 (96.6%) 5 (8.6%) 56 (96.6%) 5 (8.6%)
Controls n = 50 44 (88%) 1 (2%) 49 (98%) 0 49 (98%) 3 (6%)
P 1.0 .6222 1 .0601 1.0 .7224
Abbreviations: CMV, cytomegalovirus; EBV‐CA, Epstein‐Barr virus capsid antigen; ELISA, enzyme‐
linked immunosorbent assay; HHV‐6, herpesvirus‐6; IgG, immunoglobulin G; IgM, immunoglobulin M;
ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome.
TABLE 3 EBV, CMV, and HHV‐6 DNA in
plasma and PBMCs samples
CMV DNA positive EBV DNA positive HHV‐6 DNA positive
Plasma PBMCs Plasma PBMCs Plasma PBMCs
n (%) n (%) n (%) n (%) n (%) n (%)
Patients with ME/
CFS n = 58
2 (3.4%) 43 (74.1%) 14 (24.1%) 47 (81.0%) 1 (1.7%) 48 (82.8%)
Controls n = 50 0 (0%) 39 (78%) 2 (4%) 42 (84%) 0 (0%) 41 (82%)
P .4981 .6597 .0052 .8018 1 1
Abbreviations: CMV, cytomegalovirus; EBV, Epstein‐Barr virus; ELISA, enzyme‐linked
immunosorbent assay; HHV‐6, herpesvirus‐6; ME/CFS, myalgic encephalomyelitis/chronic fatigue
syndrome; PBMC, peripheral blood mononuclear cell.
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3.3 | Prevalence of active CMV, EBV, and HHV‐6
infection
Criteria for active CMV, EBV, and HHV‐6 infection (Table 4) included
presence of viral genome sequences in plasma with virus‐specific IgM
class antibodies positivity and/or viral genome sequences in plasma
with elevated titers of virus‐specific IgG class antibodies (R/Iv>5)
without IgM antibodies.11 The cases positive for virus‐specific IgG
class antibodies and virus DNA in PBMCs were considered as a latent
viral infections.
All positive for CMV and HHV‐6 DNA plasma samples from
ME/CFS cases were negative for virus‐specific IgM class anti-
bodies, also elevated titers of virus‐specific IgG class antibodies
were not found. Therefore, these cases were considered as latent
viral infections (Table 5). Fourteen plasma samples from ME/CFS
cases and two from the control group were positive for EBV DNA
sequences. Nine of these ME/CFS cases were with elevated titers
of EBV‐CA IgG class antibodies as well, two were both EBV‐CA
IgM positive and with elevated titers of virus‐specific IgG class
antibodies, and one was only EBV‐CA IgM positive. Considering
the criteria for active infection, 12 patients with ME/CFS were
estimated with active EBV infection. In the control group, one
individual was regarded with active EBV infection (EBV DNA
in plasma sample and elevated titers of EBV VCA IgG class
antibodies). The analysis showed that the difference in the pre-
valence of active EBV infection between ME/CFS patients and
healthy controls was statistically significant (P = .0027). No sub-
stantial difference in profiles of symptoms between CFS/ME
patients with active and persistent EBV infection was observed.
We assessed the number of EBV DNA copies in plasma samples
of ME/CFS patients with active EBV infection by quantitative PCR.
EBV DNA loads were relatively low, in the range between 790 and
1540 copies/mL of plasma samples.
4 | DISCUSSION
Association of herpesviruses CMV, EBV, and HHV‐6 with
ME/CFS has been investigated for long time, however the results
are inconsistent.9‐11,13,15,23‐26 To contribute to the understanding of
ME/CFS, in the present study, we continued these investigations and
determined prevalence and type of CMV, EBV, and HHV‐6 infections
among Bulgarian patients with ME/CFS. We have simultaneously
tested ME/CFS patients and healthy controls for the presence
of CMV, EBV, and HHV‐6 DNAs in cell‐free plasma and PBMCs
samples as well for the virus‐specific antibodies.
The key finding of this study is the higher prevalence of EBV
active infection (presence of viral genome sequences in plasma with
EBV‐CA IgM positivity and/or viral genomic sequences in plasma
with elevated titers of EBV‐CA IgG without EBV‐CA IgM) observed in
patients with ME/CFS compared to the controls (P = .0027). EBNA‐1
IgG positivity of these cases indicated reactivation of a latent virus
infection rather than primary EBV infection. At the same time, the
prevalence of latent EBV infection (EBV‐CA IgG and/or PBMCs EBV
DNA positivity) was high but quite similar in both ME/CFS patients
and controls. Many previous studies have shown that EBV is a
common trigger of ME/CFS and a possible key factors in the devel-
opment of the disease. In a subset of patients with ME/CFS, the
disease starts with infectious mononucleosis. In addition, altered
serological profiling of the EBV immune response has been demon-
strated in ME/CFS cases indicating that the immune system of some
patients with ME/CFS interact with the EBV in a way different from
that of healthy controls.27 Thus, Lerner et al23,24 found serum IgM
class antibodies to EBV‐CA in patients with ME/CFS but not in
controls and also reported elevated antibodies against EBV‐dUTPase
and EBV DNA polymerase in a subset of patients with ME/CFS.
Furthermore, elevated titers of early antigen (EA) IgG and antibodies
to ZEBRA, a product of the immediate‐early EBV gene BZLF‐1, were
TABLE 4 Criteria for active viral infectiona




Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M.
aThe criteria were applied for the purpose of this study.






































CMV 2 0 0 0 0 0 NA NA NA NA
EBV 14 1 9 2 12 2 0 1 0 1
HHV‐6 1 0 0 0 0 0 NA NA NA NA
Abbreviations: CFS, chronic fatigue syndrome; CMV, cytomegalovirus; EBV, Epstein‐Barr virus; ELISA, enzyme‐linked immunosorbent assay; HHV‐6,
herpesvirus‐6; IgG, immunoglobulin G; IgM, immunoglobulin M; nPCR, nested polymerase chain reaction.
3686 | SHIKOVA ET AL.
detected in patients with ME/CFS.28,29 Loebel et al30 in subsets of
EBV‐positive ME/CFS patients have found elevated IgM response
against EBV‐CA but a lack of antibodies against EBNA‐1. In a further
global screening of serum antibody responses to an EBV peptide
array, the same authors in serum of patients with ME/CFS revealed
quite similar EBV IgG antibody response pattern as in sera of healthy
controls except for the significantly enhanced IgG responses to
several EBNA‐6 peptides.25 On the contrary, according to a recent
study, no increased EBV‐CA IgG reactivity over EBNA‐1 in ME/CFS
cohorts is found and EBNA‐6 peptide IgG reactivity is not
significantly different between the ME/CFS and healthy control
samples.27 In addition, some earlier studies also reported no
differences in IgG titers against EBV‐CA, EBNA‐1 and EA.10,26,31 In
our present study, we observed elevated EBV‐CA IgG antibodies in
most of ME/CFS patients with active EBV infection. At the same time,
we do not detect a significant difference in EBV‐CA IgG and IgM
positivity rates between patients with ME/CFS and the control group.
There are fewеr studies on EBV DNA detection in different types
of samples from patients with ME/CFS and its link to the develop-
ment of ME/CFS. Thus, Loebel et al30 have compared EBV load in
blood immune cells and found more frequently EBER DNA but not
BZLF‐1 RNA in patients with ME/CFS compared to the healthy
controls suggesting more frequent latent replication in ME/CFS.
However, in a later study, they observed similar prevalence of EBV
DNA in throat washings in patients with ME/CFS compared to
healthy controls, indicating no pathogenic role of EBV reactivation in
ME/CFS.25 At the same time, Fiore et al32 described a ME/CFS case
with actively replicating EBV in blood.
All these conflicting results may be attributed to the methodo-
logical differences, not well‐characterized patients with ME/CFS,
pathogenesis‐related EBV genetic variants, and heterogeneity of
studied ME/CFS populations.33 Thus, heterogeneity among patients
with ME/CFS is well recognized and subtypes of ME/CFS may reflect
particular etiological factors.34 Zhang et al found evidence of subtype‐
specific relationships for EBV among patients with ME/CFS analyzing
EBV antibody markers in patients with ME/CFS which had been
grouped into eight subtypes based on clustering of real‐time PCR
expression data for 88 CFS/ME‐associated genes, 12 of them asso-
ciated with EBV infection. It is assumed that heterogeneous host re-
sponse to EBV reactivation could explain the heterogeneous
occurrence of many of the immune and neurological abnormalities
reported in patients with CFS/ME.15,35
Our results based on serological as well as on PCR‐based tech-
niques distinguishing between active and latent infection have also
shown that there are no significant differences in the frequency of
CMV and HHV‐6 active infection in patients with ME/CFS compared
to the control group. We also detected high but quite similar fre-
quency rates of CMV and HHV‐6 latent infection among both, ME/
CFS and control groups. These results confirm some previous studies
indicating no correlation between CMV and HHV‐6 infection and
ME/CFS.10,14,22,26,36 At the same time, other studies indicate such
a link.37‐39 Moreover, an association between active HHV‐6 infection
and ME/CFS has been demonstrated in studies distinguishing
between active and latent infection using immunofluorescence as-
says directed against HHV‐6A antigens or early antibody assays.40,41
Active HHV‐6 infection was detected more often in patients with
ME/CFS than in controls, and this infection correlated with the
occurrence of the clinical symptoms.11 In a recent meta‐analysis,
however, we were not able to find a statistically significant difference
between reported studies that have found no correlation between
HHV‐6 and ME/CFS and publications that noted a correlation.13
The present study had some limitations including the small size
of studied ME/CFS population, a potential limitation of methodology
approach for estimating elevated levels of virus‐specific antibodies,
the results are indicative for characterization of herpesvirus infection
at a particular moment and not for the entire course of the disease.
In conclusion, this study using both serological and PCR‐based
techniques for distinguishing between active and latent infection
showed a high rate of active EBV infection among patients with ME/
CFS indicating that at least in a subset of cases, EBV is an important
factor for the development of the disease.
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